Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20686559 | 1.00 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL16481683 | 1.00 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL16466564 | 1.00 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL16481626 | 0.93 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL16481577 | 0.93 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL16481589 | 0.93 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL17184185 | 0.91 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL17184218 | 0.91 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL16481765 | 0.91 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL16481700 | 0.91 | IRAK4 (1.00) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021011868-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200069668-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| US-20200069668-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20170035881-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-02-09 | — | — | US | disclosed |
| US-20170035881-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885 |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885 |
| US-20170035881-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885 |
| US-20200069668-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.